BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31396764)

  • 1. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
    Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
    Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
    Wang Z; Duan X; Lv Y; Zhao Y
    Life Sci; 2019 Dec; 239():117013. PubMed ID: 31678287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity.
    Yang F; Li A; Liu H; Zhang H
    Drug Des Devel Ther; 2018; 12():3321-3333. PubMed ID: 30323564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
    Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
    Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
    Duan W; Liu Y
    Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
    Li T; Zhang Y; Meng YP; Bo LS; Ke WB
    Pharm Res; 2017 Dec; 34(12):2710-2719. PubMed ID: 29181687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.
    Wu H; Wang C; Sun J; Sun L; Wan J; Wang S; Gu D; Yu C; Yang C; He J; Zhang Z; Lv Y; Wang H; Yao M; Qin W; Wang C; Jin H
    ACS Appl Mater Interfaces; 2019 Nov; 11(47):43996-44006. PubMed ID: 31682099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
    Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
    Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
    Ye J; Zhang R; Chai W; Du X
    Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles.
    Wang H; Sun S; Zhang Y; Wang J; Zhang S; Yao X; Chen L; Gao Z; Xie B
    Drug Deliv; 2019 Dec; 26(1):89-97. PubMed ID: 30744448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
    Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
    Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics.
    Zheng X; Zhang F; Zhao Y; Zhang J; Dawulieti J; Pan Y; Cui L; Sun M; Shao D; Li M; He K; Zhang M; Li J; Chen L
    Theranostics; 2018; 8(14):3808-3823. PubMed ID: 30083261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-Loaded Ligand-Functionalized Polymer-Lipid Hybrid Nanoparticles for Enhanced Therapeutic Effect Against Liver Cancer.
    Tang S; Li Y
    J Nanosci Nanotechnol; 2019 Nov; 19(11):6866-6871. PubMed ID: 31039838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
    Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
    Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
    [No Abstract]   [Full Text] [Related]  

  • 20. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
    Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
    Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.